Recommendation to include hydroxyethyl (meth)acrylate in the British Baseline Patch Test Series

S. Rolls (Lead / Corresponding author), M. M. Chowdhury, S. Cooper, P. Cousen, A. M. Flynn, S. A. Ghaffar, C. M. Green, A. Haworth, C. Holden, G. A. Johnston, K. Naidoo, D. I. Orton, C. Reckling, R. A. Sabroe, M. Scorer, N. M. Stone, D. Thompson, S. Wakelin, M. Wilkinson, D. A. Buckley

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Background: (Meth)acrylates are potent sensitizers and a common cause of allergic contact dermatitis (ACD). The frequency of (meth)acrylate ACD has increased with soaring demand for acrylic nails. A preliminary audit has suggested a significant rate of positive patch tests to (meth)acrylates using aimed testing in patients providing a clear history of exposure. To date, (meth)acrylates have not been routinely tested in the baseline patch test series in the U.K. and Europe.

    Objectives: To determine whether inclusion of 2-hydroxyethyl methacrylate (2-HEMA) 2% in petrolatum (pet.) in the baseline series detects cases of treatable (meth)acrylate ACD.

    Methods: During 2016–2017, 15 U.K. dermatology centres included 2-HEMA in the extended baseline patch test series. Patients with a history of (meth)acrylate exposure, or who tested positive to 2-HEMA, were selectively tested with a short series of eight (meth)acrylate allergens.

    Results: In total 5920 patients were consecutively patch tested with the baseline series, of whom 669 were also tested with the (meth)acrylate series. Overall, 102 of 5920 (1·7%) tested positive to 2-HEMA and 140 (2·4%) to at least one (meth)acrylate. Had 2-HEMA been excluded from the baseline series, (meth)acrylate allergy would have been missed in 36 of 5920 (0·6% of all patients). The top (meth)acrylates eliciting a positive reaction were 2-HEMA (n = 102, 1·7%), 2-hydroxypropyl methacrylate (n = 61, 1·0%) and 2-hydroxyethyl acrylate (n = 57, 1·0%).

    Conclusions: We recommend that 2-HEMA 2% pet. be added to the British baseline patch test series. We also suggest a standardized short (meth)acrylate series, which is likely to detect most cases of (meth)acrylate allergy.

    Original languageEnglish
    Number of pages17
    JournalBritish Journal of Dermatology
    Early online date31 Jan 2019
    DOIs
    Publication statusE-pub ahead of print - 31 Jan 2019

    Fingerprint

    Patch Tests
    Acrylates
    Allergic Contact Dermatitis
    Petrolatum
    Hypersensitivity
    acrylic acid
    Nails
    Dermatology
    hydroxyethyl methacrylate
    Allergens

    Cite this

    Rolls, S., Chowdhury, M. M., Cooper, S., Cousen, P., Flynn, A. M., Ghaffar, S. A., ... Buckley, D. A. (2019). Recommendation to include hydroxyethyl (meth)acrylate in the British Baseline Patch Test Series. British Journal of Dermatology. https://doi.org/10.1111/bjd.17708
    Rolls, S. ; Chowdhury, M. M. ; Cooper, S. ; Cousen, P. ; Flynn, A. M. ; Ghaffar, S. A. ; Green, C. M. ; Haworth, A. ; Holden, C. ; Johnston, G. A. ; Naidoo, K. ; Orton, D. I. ; Reckling, C. ; Sabroe, R. A. ; Scorer, M. ; Stone, N. M. ; Thompson, D. ; Wakelin, S. ; Wilkinson, M. ; Buckley, D. A. / Recommendation to include hydroxyethyl (meth)acrylate in the British Baseline Patch Test Series. In: British Journal of Dermatology. 2019.
    @article{bf57bcba66394d58ac7fb8e5460a46e2,
    title = "Recommendation to include hydroxyethyl (meth)acrylate in the British Baseline Patch Test Series",
    abstract = "Background: (Meth)acrylates are potent sensitizers and a common cause of allergic contact dermatitis (ACD). The frequency of (meth)acrylate ACD has increased with soaring demand for acrylic nails. A preliminary audit has suggested a significant rate of positive patch tests to (meth)acrylates using aimed testing in patients providing a clear history of exposure. To date, (meth)acrylates have not been routinely tested in the baseline patch test series in the U.K. and Europe.Objectives: To determine whether inclusion of 2-hydroxyethyl methacrylate (2-HEMA) 2{\%} in petrolatum (pet.) in the baseline series detects cases of treatable (meth)acrylate ACD.Methods: During 2016–2017, 15 U.K. dermatology centres included 2-HEMA in the extended baseline patch test series. Patients with a history of (meth)acrylate exposure, or who tested positive to 2-HEMA, were selectively tested with a short series of eight (meth)acrylate allergens.Results: In total 5920 patients were consecutively patch tested with the baseline series, of whom 669 were also tested with the (meth)acrylate series. Overall, 102 of 5920 (1·7{\%}) tested positive to 2-HEMA and 140 (2·4{\%}) to at least one (meth)acrylate. Had 2-HEMA been excluded from the baseline series, (meth)acrylate allergy would have been missed in 36 of 5920 (0·6{\%} of all patients). The top (meth)acrylates eliciting a positive reaction were 2-HEMA (n = 102, 1·7{\%}), 2-hydroxypropyl methacrylate (n = 61, 1·0{\%}) and 2-hydroxyethyl acrylate (n = 57, 1·0{\%}).Conclusions: We recommend that 2-HEMA 2{\%} pet. be added to the British baseline patch test series. We also suggest a standardized short (meth)acrylate series, which is likely to detect most cases of (meth)acrylate allergy.",
    author = "S. Rolls and Chowdhury, {M. M.} and S. Cooper and P. Cousen and Flynn, {A. M.} and Ghaffar, {S. A.} and Green, {C. M.} and A. Haworth and C. Holden and Johnston, {G. A.} and K. Naidoo and Orton, {D. I.} and C. Reckling and Sabroe, {R. A.} and M. Scorer and Stone, {N. M.} and D. Thompson and S. Wakelin and M. Wilkinson and Buckley, {D. A.}",
    note = "{\circledC} 2019 British Association of Dermatologists.",
    year = "2019",
    month = "1",
    day = "31",
    doi = "10.1111/bjd.17708",
    language = "English",
    journal = "British Journal of Dermatology",
    issn = "0007-0963",
    publisher = "Wiley",

    }

    Rolls, S, Chowdhury, MM, Cooper, S, Cousen, P, Flynn, AM, Ghaffar, SA, Green, CM, Haworth, A, Holden, C, Johnston, GA, Naidoo, K, Orton, DI, Reckling, C, Sabroe, RA, Scorer, M, Stone, NM, Thompson, D, Wakelin, S, Wilkinson, M & Buckley, DA 2019, 'Recommendation to include hydroxyethyl (meth)acrylate in the British Baseline Patch Test Series', British Journal of Dermatology. https://doi.org/10.1111/bjd.17708

    Recommendation to include hydroxyethyl (meth)acrylate in the British Baseline Patch Test Series. / Rolls, S. (Lead / Corresponding author); Chowdhury, M. M.; Cooper, S.; Cousen, P.; Flynn, A. M.; Ghaffar, S. A.; Green, C. M.; Haworth, A.; Holden, C.; Johnston, G. A.; Naidoo, K.; Orton, D. I.; Reckling, C.; Sabroe, R. A.; Scorer, M.; Stone, N. M.; Thompson, D.; Wakelin, S.; Wilkinson, M.; Buckley, D. A.

    In: British Journal of Dermatology, 31.01.2019.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Recommendation to include hydroxyethyl (meth)acrylate in the British Baseline Patch Test Series

    AU - Rolls, S.

    AU - Chowdhury, M. M.

    AU - Cooper, S.

    AU - Cousen, P.

    AU - Flynn, A. M.

    AU - Ghaffar, S. A.

    AU - Green, C. M.

    AU - Haworth, A.

    AU - Holden, C.

    AU - Johnston, G. A.

    AU - Naidoo, K.

    AU - Orton, D. I.

    AU - Reckling, C.

    AU - Sabroe, R. A.

    AU - Scorer, M.

    AU - Stone, N. M.

    AU - Thompson, D.

    AU - Wakelin, S.

    AU - Wilkinson, M.

    AU - Buckley, D. A.

    N1 - © 2019 British Association of Dermatologists.

    PY - 2019/1/31

    Y1 - 2019/1/31

    N2 - Background: (Meth)acrylates are potent sensitizers and a common cause of allergic contact dermatitis (ACD). The frequency of (meth)acrylate ACD has increased with soaring demand for acrylic nails. A preliminary audit has suggested a significant rate of positive patch tests to (meth)acrylates using aimed testing in patients providing a clear history of exposure. To date, (meth)acrylates have not been routinely tested in the baseline patch test series in the U.K. and Europe.Objectives: To determine whether inclusion of 2-hydroxyethyl methacrylate (2-HEMA) 2% in petrolatum (pet.) in the baseline series detects cases of treatable (meth)acrylate ACD.Methods: During 2016–2017, 15 U.K. dermatology centres included 2-HEMA in the extended baseline patch test series. Patients with a history of (meth)acrylate exposure, or who tested positive to 2-HEMA, were selectively tested with a short series of eight (meth)acrylate allergens.Results: In total 5920 patients were consecutively patch tested with the baseline series, of whom 669 were also tested with the (meth)acrylate series. Overall, 102 of 5920 (1·7%) tested positive to 2-HEMA and 140 (2·4%) to at least one (meth)acrylate. Had 2-HEMA been excluded from the baseline series, (meth)acrylate allergy would have been missed in 36 of 5920 (0·6% of all patients). The top (meth)acrylates eliciting a positive reaction were 2-HEMA (n = 102, 1·7%), 2-hydroxypropyl methacrylate (n = 61, 1·0%) and 2-hydroxyethyl acrylate (n = 57, 1·0%).Conclusions: We recommend that 2-HEMA 2% pet. be added to the British baseline patch test series. We also suggest a standardized short (meth)acrylate series, which is likely to detect most cases of (meth)acrylate allergy.

    AB - Background: (Meth)acrylates are potent sensitizers and a common cause of allergic contact dermatitis (ACD). The frequency of (meth)acrylate ACD has increased with soaring demand for acrylic nails. A preliminary audit has suggested a significant rate of positive patch tests to (meth)acrylates using aimed testing in patients providing a clear history of exposure. To date, (meth)acrylates have not been routinely tested in the baseline patch test series in the U.K. and Europe.Objectives: To determine whether inclusion of 2-hydroxyethyl methacrylate (2-HEMA) 2% in petrolatum (pet.) in the baseline series detects cases of treatable (meth)acrylate ACD.Methods: During 2016–2017, 15 U.K. dermatology centres included 2-HEMA in the extended baseline patch test series. Patients with a history of (meth)acrylate exposure, or who tested positive to 2-HEMA, were selectively tested with a short series of eight (meth)acrylate allergens.Results: In total 5920 patients were consecutively patch tested with the baseline series, of whom 669 were also tested with the (meth)acrylate series. Overall, 102 of 5920 (1·7%) tested positive to 2-HEMA and 140 (2·4%) to at least one (meth)acrylate. Had 2-HEMA been excluded from the baseline series, (meth)acrylate allergy would have been missed in 36 of 5920 (0·6% of all patients). The top (meth)acrylates eliciting a positive reaction were 2-HEMA (n = 102, 1·7%), 2-hydroxypropyl methacrylate (n = 61, 1·0%) and 2-hydroxyethyl acrylate (n = 57, 1·0%).Conclusions: We recommend that 2-HEMA 2% pet. be added to the British baseline patch test series. We also suggest a standardized short (meth)acrylate series, which is likely to detect most cases of (meth)acrylate allergy.

    UR - http://www.scopus.com/inward/record.url?scp=85064716787&partnerID=8YFLogxK

    U2 - 10.1111/bjd.17708

    DO - 10.1111/bjd.17708

    M3 - Article

    JO - British Journal of Dermatology

    JF - British Journal of Dermatology

    SN - 0007-0963

    ER -